Literature DB >> 19336517

Phosphorylated 4E-BP1 is associated with poor survival in melanoma.

Kathryn E O'Reilly1, Melanie Warycha, Michael A Davies, Vanessa Rodrik, Xi K Zhou, Herman Yee, David Polsky, Anna C Pavlick, Neal Rosen, Nina Bhardwaj, Gordon Mills, Iman Osman.   

Abstract

PURPOSE: Both phosphatidylinositol 3-kinase/AKT and RAS/mitogen-activated protein kinase signal transduction pathways mediate 4E-BP1 phosphorylation, releasing 4E-BP1 from the mRNA cap and permitting translation initiation. Given the prevalence of PTEN and BRAF mutations in melanoma, we first examined translation initiation, as measured by phosphorylated 4E-BP1 (p-4E-BP1), in metastatic melanoma tissues and cell lines. We then tested the association between amounts of total and p-4E-BP1 and patient survival. EXPERIMENTAL
DESIGN: Seven human metastatic melanoma cells lines and 72 metastatic melanoma patients with accessible metastatic tumor tissues and extended follow-up information were studied. Expression of 4E-BP1 transcript, total 4E-BP1 protein, and p-4E-BP1 was examined. The relationship between 4E-BP1 transcript and protein expression was assessed in a subset of patient tumors (n = 41). The association between total and p-4E-BP1 levels and survival was examined in the larger cohort of patients (n = 72).
RESULTS: 4E-BP1 was hyperphosphorylated in 4 of 7 melanoma cell lines harboring both BRAF and PTEN mutations compared with untransformed melanocytes or RAS/RAF/PTEN wild-type melanoma cells. 4E-BP1 transcript correlated with 4E-BP1 total protein levels as measured by the semiquantitative reverse-phase protein array (P = 0.012). High levels of p-4E-BP1 were associated with worse overall and post-recurrence survival (P = 0.02 and 0.0003, respectively).
CONCLUSION: Our data show that translation initiation is a common event in human metastatic melanoma and correlates with worse prognosis. Therefore, effective inhibition of the pathways responsible for 4E-BP1 phosphorylation should be considered to improve the treatment outcome of metastatic melanoma patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19336517      PMCID: PMC3995540          DOI: 10.1158/1078-0432.CCR-08-2336

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  Melanoma.

Authors:  Arlo J Miller; Martin C Mihm
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

Review 3.  mTOR, translation initiation and cancer.

Authors:  Y Mamane; E Petroulakis; O LeBacquer; N Sonenberg
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

Review 4.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

5.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

Authors:  Vikas K Goel; Alexander J F Lazar; Carla L Warneke; Mark S Redston; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

6.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells.

Authors:  Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

Review 7.  Genetic alterations in signaling pathways in melanoma.

Authors:  Frank G Haluska; Hensin Tsao; Helen Wu; Frank S Haluska; Alexander Lazar; Vikas Goel
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

8.  Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells.

Authors:  Svetlana Avdulov; Shunan Li; Van Michalek; David Burrichter; Mark Peterson; David M Perlman; J Carlos Manivel; Nahum Sonenberg; Douglas Yee; Peter B Bitterman; Vitaly A Polunovsky
Journal:  Cancer Cell       Date:  2004-06       Impact factor: 31.743

Review 9.  Signaling control of mRNA translation in cancer pathogenesis.

Authors:  Eric C Holland; Nahum Sonenberg; Pier Paolo Pandolfi; George Thomas
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

10.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.

Authors:  Hans-Guido Wendel; Elisa De Stanchina; Jordan S Fridman; Abba Malina; Sagarika Ray; Scott Kogan; Carlos Cordon-Cardo; Jerry Pelletier; Scott W Lowe
Journal:  Nature       Date:  2004-03-18       Impact factor: 49.962

View more
  28 in total

1.  High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.

Authors:  Paige Yellen; Mahesh Saqcena; Darin Salloum; Jiangnan Feng; Angela Preda; Limei Xu; Vanessa Rodrik-Outmezguine; David A Foster
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma.

Authors:  Chi-Ju Yeh; Wen-Yu Chuang; Yin-Kai Chao; Yun-Hen Liu; Yu-Sun Chang; Shao-Yun Kuo; Chen-Kan Tseng; Hsien-Kun Chang; Chuen Hsueh
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

3.  MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas.

Authors:  Michal Grzmil; Roland M Huber; Daniel Hess; Stephan Frank; Debby Hynx; Gerald Moncayo; Dominique Klein; Adrian Merlo; Brian A Hemmings
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

4.  Translation regulation in skin cancer from a tRNA point of view.

Authors:  Katerina Grafanaki; Dimitrios Anastasakis; George Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; Constantinos Stathopoulos
Journal:  Epigenomics       Date:  2018-12-19       Impact factor: 4.778

5.  Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.

Authors:  Ahmad Al-Moujahed; Fotini Nicolaou; Katarzyna Brodowska; Thanos D Papakostas; Anna Marmalidou; Bruce R Ksander; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-29       Impact factor: 4.799

6.  Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis.

Authors:  Mona Diab-Assaf; Raefa Abou-Khouzam; Nina Saadallah-Zeidan; Khaled Habib; Nizar Bitar; Walid Karam; Bertrand Liagre; Steve Harakeh; Rania Azar
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

7.  Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation.

Authors:  Michael Jewer; Scott D Findlay; Lynne-Marie Postovit
Journal:  J Cell Commun Signal       Date:  2012-10-09       Impact factor: 5.782

8.  mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features.

Authors:  Emir Ahmed Sajjad; Grzegorz Zieliński; Maria Maksymowicz; Łukasz Hutnik; Tomasz Bednarczuk; Paweł Włodarski
Journal:  Endocr Pathol       Date:  2013-03       Impact factor: 3.943

9.  Chemoproteomic Profiling Uncovers CDK4-Mediated Phosphorylation of the Translational Suppressor 4E-BP1.

Authors:  Dylan C Mitchell; Arya Menon; Amanda L Garner
Journal:  Cell Chem Biol       Date:  2019-05-02       Impact factor: 8.116

10.  Targeting TOR dependence in cancer.

Authors:  Matthew R Janes; David A Fruman
Journal:  Oncotarget       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.